Compare Adaptive Biotechnologies Corp (ADPT) vs Box Inc (BOX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Box Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.93 (market cap $3.33B), while Box Inc trades at $28.94 (market cap $4.00B). The key difference: Box Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Box Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | BOX | |
|---|---|---|
Market Cap | $3.33B | $4.00B |
Sector | Health | Technology |
52-Week High | $22.37 | $33.73 |
52-Week Low | $10.24 | $21.37 |
Enterprise Value | $3.19B | $4.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BOX trades at $28.85, up 3.44% today, with a bullish technical signal from moving averages and strong analyst consensus. Revenue grew to $1.09B in 2025, with net income surging to $244.62M, though Q2 2026 EPS is expected at $0.4. The company expanded Box Zones to new regions, enhancing global data governance capabilities.
The outlook is positive with a $37 consensus price target, but risks include high P/E of 44.3 and overbought RSI levels. Earnings growth and strategic expansions present opportunities, yet investor caution is warranted near-term due to valuation and potential volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →
